• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    2/12/26 5:00:37 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Beta Bionics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    08659B102

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus BB SPV, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.00 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB SPV, LLC ("Soleus BB") and Soleus Private Equity Fund I, L.P. ("Soleus PE Fund I"), and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus BB, Soleus PE Fund I, Soleus Private Equity Fund II, L.P. ("Soleus PE Fund II"), and Soleus Capital Master Fund, L.P. ("Master Fund" and, together with Soleus BB, Soleus PE Fund I and Soleus PE Fund II, the "Soleus Funds"), and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of the common stock of Beta Bionics, Inc. (the "Issuer") outstanding as of October 24, 2025, as set forth on the cover of the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 that was filed with the Securities and Exchange Commission on October 28, 2025 (the "Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Private Equity Fund I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.00 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB and Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC and Soleus GP, LLC. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Private Equity GP I, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.00 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB and Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC and Soleus GP, LLC. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus PE GP I, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.00 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB and Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC and Soleus GP, LLC. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Private Equity Fund II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,703,961.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,703,961.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,703,961.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE Fund II. Soleus Private Equity GP II, LLC is the sole general partner of Soleus PE Fund II, and Soleus PE GP II, LLC is the sole manager of Soleus Private Equity GP II, LLC. SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of Soleus PE GP II, LLC, Soleus Private Equity GP II, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Soleus PE Fund II other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Private Equity GP II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,703,961.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,703,961.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,703,961.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE Fund II. Soleus Private Equity GP II, LLC is the sole general partner of Soleus PE Fund II, and Soleus PE GP II, LLC is the sole manager of Soleus Private Equity GP II, LLC. SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of Soleus PE GP II, LLC, Soleus Private Equity GP II, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Soleus PE Fund II other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus PE GP II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,703,961.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,703,961.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,703,961.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Soleus PE Fund II. Soleus Private Equity GP II, LLC is the sole general partner of Soleus PE Fund II, and Soleus PE GP II, LLC is the sole manager of Soleus Private Equity GP II, LLC. SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of Soleus PE GP II, LLC, Soleus Private Equity GP II, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Soleus PE Fund II other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Capital Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    799,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    799,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    799,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.8 %
    12Type of Reporting Person (See Instructions)

    FI

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    799,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    799,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    799,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Capital Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    799,817.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    799,817.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    799,817.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus Capital Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,503,778.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,503,778.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,503,778.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by the Soleus Funds. Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB and Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Private Equity GP II, LLC is the sole general partner of Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of Soleus PE GP I, LLC, Soleus Private Equity GP I, LLC, Soleus PE GP II, LLC, Soleus Private Equity GP II, LLC, SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by the Soleus Funds other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Soleus GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,503,778.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,503,778.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,503,778.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.7 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by the Soleus Funds. Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB and Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Private Equity GP II, LLC is the sole general partner of Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of Soleus PE GP I, LLC, Soleus Private Equity GP I, LLC, Soleus PE GP II, LLC, Soleus Private Equity GP II, LLC, SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by the Soleus Funds other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    08659B102


    1Names of Reporting Persons

    Guy Levy
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    30,787.00
    6Shared Voting Power

    2,503,778.00
    7Sole Dispositive Power

    30,787.00
    8Shared Dispositive Power

    2,503,778.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,534,565.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) The shares reported in the table above are held directly by the Soleus Funds. Soleus Private Equity GP I, LLC is the sole general partner of Soleus BB and Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Private Equity GP II, LLC is the sole general partner of Soleus PE Fund I, and Soleus PE GP I, LLC is the sole manager of Soleus Private Equity GP I, LLC. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for the Soleus Funds, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP I, LLC, Soleus PE GP II, LLC, and Soleus GP, LLC. Each of Soleus PE GP I, LLC, Soleus Private Equity GP I, LLC, Soleus PE GP II, LLC, Soleus Private Equity GP II, LLC, SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by the Soleus Funds other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose. (2) The percentage listed in row 11 is calculated based upon 44,024,631 shares of common stock of the Issuer outstanding as of October 24, 2025, as set forth on the cover of the Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Beta Bionics, Inc.
    (b)Address of issuer's principal executive offices:

    11 Hughes Irvine, California 92618
    Item 2. 
    (a)Name of person filing:

    Soleus BB SPV, LLC Soleus Private Equity Fund I, L.P. Soleus Private Equity GP I, LLC Soleus PE GP I, LLC Soleus Private Equity Fund II, L.P. Soleus Private Equity GP II, LLC Soleus PE GP II, LLC Soleus Capital Master Fund, L.P. Soleus Capital, LLC Soleus Capital Group, LLC Soleus Capital Management, L.P. Soleus GP, LLC Guy Levy
    (b)Address or principal business office or, if none, residence:

    Soleus BB SPV, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Private Equity Fund I, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Private Equity GP I, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus PE GP I, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Private Equity Fund II, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Private Equity GP II, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus PE GP II, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital Master Fund, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital Group, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus Capital Management, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830 Soleus GP, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830 Guy Levy c/o Soleus Capital Management, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830
    (c)Citizenship:

    Soleus BB SPV, LLC - Delaware Soleus Private Equity Fund I, L.P. - Delaware Soleus Private Equity GP I, LLC - Delaware Soleus PE GP I, LLC - Delaware Soleus Private Equity Fund II, L.P. - Delaware Soleus Private Equity GP II, LLC - Delaware Soleus PE GP II, LLC - Delaware Soleus Capital Master Fund, L.P. - Cayman Islands Soleus Capital, LLC - Delaware Soleus Capital Group, LLC - Delaware Soleus Capital Management, L.P. - Delaware Soleus GP, LLC - Delaware Guy Levy - United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    08659B102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information in rows 5 through 9 and 11 on the cover pages to this Schedule 13G, including the footnotes thereto, which reflects beneficial ownership of the Common Stock of the Issuer as of Mach 31, 2025, is hereby incorporated by reference. Soleus BB SPV, LLC - 0 Soleus Private Equity Fund I, L.P. - 0 Soleus Private Equity GP I, LLC - 0 Soleus PE GP I, LLC - 0 Soleus Private Equity Fund II, L.P. - 1,703,961 Soleus Private Equity GP II, LLC - 1,703,961 Soleus PE GP II, LLC - 1,703,961 Soleus Capital Master Fund, L.P. - 799,817 Soleus Capital, LLC - 799,817 Soleus Capital Group, LLC - 799,817 Soleus Capital Management, L.P. - 2,503,778 Soleus GP, LLC - 2,503,778 Guy Levy - 2,503,778
    (b)Percent of class:

    Soleus BB SPV, LLC - 0% Soleus Private Equity Fund I, L.P. - 0% Soleus Private Equity GP I, LLC - 0% Soleus PE GP I, LLC - 0% Soleus Private Equity Fund II, L.P. - 3.9% Soleus Private Equity GP II, LLC - 3.9% Soleus PE GP II, LLC - 3.9% Soleus Capital Master Fund, L.P. - 1.8% Soleus Capital, LLC - 1.8% Soleus Capital Group, LLC - 1.8% Soleus Capital Management, L.P. - 5.7% Soleus GP, LLC - 5.7% Guy Levy - 5.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Guy Levy - 30,787

     (ii) Shared power to vote or to direct the vote:

    Soleus BB SPV, LLC - 0 Soleus Private Equity Fund I, L.P. - 0 Soleus Private Equity GP I, LLC - 0 Soleus PE GP I, LLC - 0 Soleus Private Equity Fund II, L.P. - 1,703,961 Soleus Private Equity GP II, LLC - 1,703,961 Soleus PE GP II, LLC - 1,703,961 Soleus Capital Master Fund, L.P. - 799,817 Soleus Capital, LLC - 799,817 Soleus Capital Group, LLC - 799,817 Soleus Capital Management, L.P. - 2,503,778 Soleus GP, LLC - 2,503,778 Guy Levy - 2,503,778

     (iii) Sole power to dispose or to direct the disposition of:

    Guy Levy - 30-787

     (iv) Shared power to dispose or to direct the disposition of:

    Soleus BB SPV, LLC - 0 Soleus Private Equity Fund I, L.P. - 0 Soleus Private Equity GP I, LLC - 0 Soleus PE GP I, LLC - 0 Soleus Private Equity Fund II, L.P. - 1,703,961 Soleus Private Equity GP II, LLC - 1,703,961 Soleus PE GP II, LLC - 1,703,961 Soleus Capital Master Fund, L.P. - 799,817 Soleus Capital, LLC - 799,817 Soleus Capital Group, LLC - 799,817 Soleus Capital Management, L.P. - 2,503,778 Soleus GP, LLC - 2,503,778 Guy Levy - 2,503,778

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Soleus BB SPV, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Private Equity Fund I, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Private Equity GP I, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus PE GP I, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Private Equity Fund II, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Private Equity GP II, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus PE GP II, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Capital Master Fund, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Capital, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Capital Group, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus Capital Management, L.P.
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Soleus GP, LLC
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy, Managing Member
    Date:02/12/2026
     
    Guy Levy
     
    Signature:/s/ Guy Levy
    Name/Title:Guy Levy
    Date:02/12/2026
    Get the next $BBNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    2/9/2026$24.00Buy
    UBS
    1/27/2026$17.00Hold
    TD Cowen
    1/9/2026Buy → Neutral
    BofA Securities
    10/21/2025$26.00Buy
    Stifel
    10/1/2025$26.00Neutral → Buy
    Goldman
    6/16/2025$26.00Buy
    Truist
    6/12/2025$30.00Buy
    Lake Street
    5/30/2025$16.00Neutral
    Goldman
    More analyst ratings

    $BBNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2025 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archi

    1/15/26 4:03:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

    IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company's management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metrics set forth below. The Company invites investors to register for in-person meetings by contacting the Company's investor relations representative at [email protected]. Preliminary, Un

    1/8/26 4:04:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026

    IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX) (the "Company"), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre-release its topline fourth quarter 2025 financial results the week of January 5, 2026. Topline financial results covered in the pre-release are expected to include net sales, new patient starts, and the percentage of new patient starts reimbursed through the pharmacy benefit plan (PBP) channel. Members of the Company's management team will host in-person meetings in San Francisco from January 12, 2026 through January 14, 2026 to discuss topline fourth quarter 2025 results.

    12/8/25 7:45:00 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 8:30:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 4:49:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)

    2/12/26 5:00:37 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)

    2/10/26 11:23:20 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)

    2/9/26 8:51:07 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Beta Bionics with a new price target

    UBS initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $24.00

    2/9/26 7:00:55 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Beta Bionics with a new price target

    TD Cowen initiated coverage of Beta Bionics with a rating of Hold and set a new price target of $17.00

    1/27/26 8:43:35 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics downgraded by BofA Securities

    BofA Securities downgraded Beta Bionics from Buy to Neutral

    1/9/26 8:48:15 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Michel Gerard J was granted 3,997 shares, increasing direct ownership by 32% to 16,544 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    1/14/26 8:30:13 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Director Palasis Maria was granted 3,997 shares, increasing direct ownership by 47% to 12,432 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    1/14/26 8:30:10 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Director Carney Sean was granted 3,997 shares, increasing direct ownership by 36% to 15,244 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    1/14/26 8:30:11 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Financials

    Live finance-specific insights

    View All

    Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2025 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archi

    1/15/26 4:03:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

    IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company's management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metrics set forth below. The Company invites investors to register for in-person meetings by contacting the Company's investor relations representative at [email protected]. Preliminary, Un

    1/8/26 4:04:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

    IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Third Quarter 2025 Financial Results & Key Metrics Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Durable Medical Equipment (DME) channel net sales of $21.0 million, up 45% compared to $14.5 million in the third quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $6.2 million, up 178% compared to $2.2 million in the thir

    10/28/25 4:02:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care